Diabetes Research and Clinical Practice · 2017 · 65 citations · 3 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyDiabetologyPharmacovigilanceDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapySodium-glucose Cotransporter 2 InhibitorsUrinary Tract Infection PharmacotherapyUrinary Tract Infection PreventionAntidiabetic Drug TherapyDiabetes Medication MonitoringDiabetes Medication UseDipeptidyl PeptidasesGenital InfectionsGenital UlcersInitiationType 2 Diabetes Treatment
AIMS: To explore the feasibility of MedicineInsight data to support risk management plan evaluation, focusing on sodium glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes. METHODS: A retrospective study using de-identified electronic general practitioner records. Patients who initiated SGLT2 inhibitor between 1 Jan 2012 to 1 Sep 2015 were compared to patients who initiated dipeptidyl peptidase 4 (DPP-4) inhibitors. The two cohorts were followed-up for six months. Risk of urinary-tract (UT) and genital infections was evaluated. The indication for use of SGLT2 inhibitors, recommended prior diabetes therapies and recommended monitoring were investigates. RESULTS: There were 1977 people in the SGLT2 cohort (with 93% initiated on dapagliflozin) and 1964 people in the DPP-4 cohort. Of the SGLT2 initiators, 54% had a documented indication for use as type 2 diabetes; 86% had used metformin and/or a sulfonylurea in the prior 12months. Renal function monitoring was documented for only 25% in the 6months initiation. The frequency of UTI in the 6months post SGLT2 initiation was not significantly increased compared to the DPP-4 cohort (3.6%vs 4.9%; aHR=0.90, 95% CI 0.66-1.24). Genital infection were more frequent in the SGLT2 than in the DPP-4 cohort (2.9% vs 0.9%, aHR=3.50, 95% CI 1.95-5.89). CONCLUSIONS: Similar to existing evidence, we found a higher risk of genital infection associated with SGLT2 inhibitors (primarily dapagliflozin) but no increased risk of UTIs compared to DPP-4 use.
3
Clifford J. Bailey, J. L. Gross, Delphine Hennicken et al. · BMC Medicine · 2013 · 356 citations · Full text
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
Christine Clar, James Alexander Gill, Rachel Court et al. · BMJ Open · 2012 · 282 citations · Full text